Ophthalmic Drug Market Size, Share Global Analysis Report, 2019–2026

Industry Insights

This professional and specialized report study examines the technical and business perspective of the global ophthalmic drug industry. The report provides a historical analysis of the industry as well as the projected trends expected to be witnessed in the global ophthalmic drug market. The report study analyzes the market statistics at the global as well as the regional levels to gain an in-depth perspective of the overall global ophthalmic drug market. The historical insights are provided from 2016 to 2019 and projected trends are provided from 2020 to 2026. The quantitative data is provided in terms of both volume (K Units) and value (USD Million) for 2016 – 2026. The qualitative data is reinforced by analyzing and providing numerous market dynamics (directly or indirectly affecting the industry) such as growth drivers, restraints, challenges, and opportunities.

We have included various industry analysis models in our report and extensively demonstrated the key business strategies and competitive landscape of the global ophthalmic drug market in our study.

Key Insights from Primary Research

• The increasing ocular disease-relatedincidences are propelling the global ophthalmic drug market, according to the primary respondents.
• The increase in R&D and drug discovery activities in the pharmaceutical sector from the past several years has significantly boosted the ophthalmic drug market.
• In some cases, the ophthalmic drugs react and cause severe side effects including irritation and blurred vision, thereby impeding the drug market.
• Novel and effective discovery of ophthalmic drugs is a laborious process owing to the stringent guidelines set by the FDA and other regulatory bodies, which eventually hampers the global market growth.
• The primary respondents stated that anti-infective drugs have been contributing significantly to the global market, capturing over one-third of the market share in terms of revenue and unit sales.

Key Recommendations from Analysts

• Based on the analytical data, the global ophthalmic market generated a revenue of over USD 27,000 million in 2019 and is projected to reach the value close to USD 37,700 million propelling at a rate of around 4.6%.
• According to analysts, the cases of ophthalmic disorders are rising considerably due to the increasing environmental pollution, especially air & water, which in turn flourishes the global ophthalmic drug market.
• Analysts indicated that North America dominated the global ophthalmic market holding over 40% market share in terms of revenue and volume.
• The drugs associated with “retinal disorders” category under the disease indication segment accounts for around one-third of the global ophthalmic market share.
• Hospital pharmacies generate considerably higher revenue through ophthalmic drug sales. However, analysts have indicated that the retail pharmacies category is anticipated to grow at a faster rate.

Global Ophthalmic Drug Market Attractiveness in 2018- By Region

Our study also includes an analysis of Porter’s Five Forces framework for understanding the competitive strategies adopted by various stakeholders involved in the entire value chain of the global ophthalmic drug market. It also encompasses PESTLE analysis and SWOT analysis.

The report also offers an in-depth analysis of the market shares of each industry player and gives an outline of the market position of key players in the global ophthalmic drug market. Moreover, the study offers wide coverage of key strategic advances witnessed in the market such as new product launches, acquisitions & mergers, collaborations & joint ventures, funding & VC activities, agreements, partnerships, R&D activities, and regional expansion of key players of the global ophthalmic drug market.

The research study provides a critical assessment of the global ophthalmic drug industry by logically segmenting the market on the basis of type, drug class, disease indication, distribution channel, and regions. Based on the past, present, and future trends, all the segments were analyzed from the bottom up, and the market sizes have been estimated from 2020 to 2026. The regional segmentation of the global ophthalmic drug industry includes the holistic bifurcation of all the five major continents including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

The visual impairment incidences have been surging considerably worldwide irrespective of the age group. This challenging situation has urged drug manufacturers and pharmaceutical companies to design and supply effective medications against this rapidly spreading disorder. Hence, the introduction of novel effective ophthalmic drug bolsters the global ophthalmic drug market. Exposure to air and water pollution poses a greater risk to the eyes. Thus, surging the demand for the drugs and propelling the global ophthalmic drug market.

The global ophthalmic drug market is segmented based on type, drug class, disease indication, distribution channel, and region. By type, the market is segmented into over-the-counter drugs and prescription drugs. Drug class classifies the market into anti-inflammatory drugs, anti-infective drugs, anti-allergic drugs, anti-glaucoma drugs, and others. Based on disease indication, the global market is categorized into inflammation/ infection, retinal disorders, dry eye, glaucoma, allergies, and others. The distribution channel segment of the global magnesium chloride market is sectored into online sales, retail pharmacies, hospital pharmacies, and others.

Report Scope

Competitive Players

Some of the essential players operating in the global ophthalmic drug market, but not restricted to include :

• Santen Pharmaceutical Co. Ltd.
• Bayer AG
• ALLERGAN
• Novartis AG
• Pfizer Inc.
• Genentech Inc.
• Oxurion NV
• Bausch Health Companies Inc.
• Regeneron Pharmaceuticals Inc.  

The global ophthalmic drug market is segmented as:

Type Segmentation Analysis

• Over-the-Counter Drugs
• Prescription Drugs

Drug Class Segmentation Analysis

• Anti-Infective Drugs
  • Anti-Bacterial Drugs
  • Anti-Fungal Drugs
  • Anti-Viral Drugs
  • Others
• Anti-Glaucoma Drugs
  • Prostaglandin Analogs
  • Alpha Agonist
  • BetaBlockers
  • Combined Medication
  • Others
• Anti-inflammatory Drugs
  • Steroids
  • Non-Steroidal Anti-Inflammatory Drugs
• Anti-Allergic Drugs
• Others

Disease Indication Segmentation Analysis

• Inflammation/ Infection
• Retinal Disorders
• Dry Eye
• Glaucoma
• Allergies
• Others

Distribution Channel Segmentation Analysis

• Online Sales
• Retail Pharmacies
• Hospital Pharmacies
• Others

Regional Segmentation Analysis

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of the Middle East & Africa

KEY BUSINESS POINTERS ADDRESSED & FOREMOST REASONS TO PROCURE THE REPORT:

• Statistical Analysis of the Past, Current, and Future Trends of the Industry with Validated Market Sizes Data
• Direct and Indirect Rationales Impacting the Industry
• In-depth and Micro Analysis of Viable Segments and Sub-segments
• Companies and Vendors Market Share, Competitive Landscape, and Player Positioning Analysis
• Demand Side (Consumption) and Supply Side (Production) Perspective and Analysis wherever applicable
• Key Buyers and End-Users Analysis
• Value Chain and Manufacturing Cost Structure Analysis wherever relevant
• Key Marketing Strategies as well as Key Sales Channels adopted in the market
• Investment Opportunity Analysis & Patents Analysis wherever feasible
• Technological Road Map & Technical Analysis
• Robust Research Methodology comprising a dynamic mix (65%~35%) of Extensive Primary Research (primary interviews, ad-hoc surveys, questionnaires) and Protracted Secondary Research (proprietary in-house database, paid external databases, publically available validated sources)